Intervention not reported
Desvenlafaxine high dose RCTs: 2 Participants: 870 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Duloxetine standard dose RCTs: 16 Participants: 4490 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
16 participants
Moderate
Intervention not reported
Duloxetine high dose RCTs: 14 Participants: 3692 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
14 participants
Moderate
Intervention not reported
Milnacipran high dose RCTs: 1 Participants: 384 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Very low
Intervention not reported
Esreboxetine standard dose RCTs: 1 Participants: 828 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Milnacipran standard dose RCTs: 2 Participants: 1298 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
Mirtazapine standard dose RCTs: 1 Participants: 422 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1116 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
6 participants
Moderate
Intervention not reported
Esreboxetine high dose RCTs: 1 Participants: 555 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Very low
Wrist fractures · pPostmenopausal women at higher risk of fractures1
It is very uncertain whether risedronate 5 mg/day changes wrist fractures compared with placebo (very low certainty).
1 finding from 1 review
RR 0.64 [0.33, 1.24]
Studies not reported
Very low
Withdrawals due to adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in withdrawals due to adverse events compared with placebo (high certainty).
1 finding from 1 review
RR 0.98 [0.9, 1.07]
Studies not reported
High
Serious adverse events · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
RR 1 [0.94, 1.07]
Studies not reported
Moderate
Clinical vertebral fractures · pPostmenopausal women at higher risk of fractures1
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Non‐vertebral fractures · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day probably leads to lower non‐vertebral fractures compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.8 [0.72, 0.9]
Studies not reported
Moderate
Hip Fracture · pPostmenopausal women at higher risk of fractures1
Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).
1 finding from 1 review
RR 0.73 [0.56, 0.94]
Studies not reported
Low
Symptoms of opioid withdrawal in the medium term · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in symptoms of opioid withdrawalfin the medium termb compared with higher doses (low certainty).
1 finding from 1 review
Serious adverse eventsg · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in serious adverse eventsg compared with higher doses (low certainty).
1 finding from 1 review
Adverse events · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
Low dose naldemedine showed no clear difference in adverse events compared with higher doses (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
It is very uncertain whether methylnaltrexone lower dose changes laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (very low certainty).
1 finding from 1 review